Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — April 2025

Genmab — April 2025

Planlagt Fastgjort Låst Flyttet Genmab
294 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • L Offline
    L Offline
    lahn1
    wrote on sidst redigeret af
    #141

    Spændende hvis de lykkes med at gøre Epco til en ny backbone treatment med mulighesd for mange forskellige combi muligheder.

    1 Reply Last reply
    0
    • SolsenS Offline
      SolsenS Offline
      Solsen
      wrote on sidst redigeret af
      #142

      Markedet ser sygt ud !

      1 Reply Last reply
      0
      • SolsenS Offline
        SolsenS Offline
        Solsen
        wrote on sidst redigeret af
        #143

        NBI nede med 7% indtil nu.

        1 Reply Last reply
        0
        • concilladoC Offline
          concilladoC Offline
          concillado
          wrote on sidst redigeret af
          #144

          Genmab A/S Share Capital Reduction.. hvad er jeres holdning/erfaring med dette?

          1 Reply Last reply
          0
          • B Offline
            B Offline
            bikube
            wrote on sidst redigeret af
            #145

            Det var da et smukt træk, lige at slette et par millioner aktier. og opkøbet kører videre til juli.

            1 Reply Last reply
            0
            • wisuwaW Offline
              wisuwaW Offline
              wisuwa
              wrote on sidst redigeret af
              #146

              Med lidt hurtig hovedregning er det ca. 1% af aktierne, no?

              1 Reply Last reply
              0
              • wisuwaW Offline
                wisuwaW Offline
                wisuwa
                wrote on sidst redigeret af
                #147

                Hvor mange % kan vi regne med at reducere via denne omgang aktietilbagekøb?

                1 Reply Last reply
                0
                • B Offline
                  B Offline
                  bikube
                  wrote on sidst redigeret af
                  #148

                  Dagens sletning er fra ca. 66,3 Mio til 64,12, det må være ca 1½%

                  1 Reply Last reply
                  0
                  • B Offline
                    B Offline
                    bikube
                    wrote on sidst redigeret af
                    #149

                    De har stadig over en Mio aktier på lager, og der forventes opkøbt ca 1½ Mio mere i det her opkøb.

                    1 Reply Last reply
                    0
                    • SolsenS Offline
                      SolsenS Offline
                      Solsen
                      wrote on sidst redigeret af
                      #150

                      Det er vel ca 3% 😉

                      1 Reply Last reply
                      0
                      • wisuwaW Offline
                        wisuwaW Offline
                        wisuwa
                        wrote on sidst redigeret af
                        #151

                        Haha jo, du har ret. 3%. Har ikke fået min aftenkaffe i dag…

                        1 Reply Last reply
                        0
                        • B Offline
                          B Offline
                          bikube
                          wrote on sidst redigeret af
                          #152

                          Og jeg er udgået for logisk tænkning. I går faldt VIXen fra 50 til 30 ca. nu er den oppe i 47. Geniet er stabilt.

                          1 Reply Last reply
                          0
                          • E Offline
                            E Offline
                            E_L
                            wrote on sidst redigeret af
                            #153

                            article in Blood - Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial https://ashpublications.org/blood/article/doi/10.1182/blood.2024026830/535030/Epcoritamab-plus-GemOx-in-transplant-ineligible

                            1 Reply Last reply
                            0
                            • G Offline
                              G Offline
                              gentogen
                              wrote on sidst redigeret af
                              #154

                              Imponerende. ORR and CR rate were 85% and 61%, respectively ( i patienter der ikke har mange muligheder)

                              1 Reply Last reply
                              0
                              • E Offline
                                E Offline
                                E_L
                                wrote on sidst redigeret af
                                #155

                                No­var­tis fol­lows Lil­ly and J&J in an­nounc­ing multi­bil­lion-dol­lar US man­u­fac­tur­ing in­vest­ment -
                                With US tar­iffs on phar­ma­ceu­ti­cals like­ly to come "very soon," an­oth­er of the world's largest drug­mak­ers is an­nounc­ing plans to beef up their Amer­i­can man­u­fac­tur­ing.

                                1 Reply Last reply
                                0
                                • E Offline
                                  E Offline
                                  E_L
                                  wrote on sidst redigeret af
                                  #156

                                  On Thurs­day, Swiss-based No­var­tis said it would in­vest $23 bil­lion in Amer­i­can man­u­fac­tur­ing and R&D over the next five years. It fol­lows sim­i­lar moves this year by In­di­anapo­lis-based Eli Lil­ly and New Jer­sey-head­quar­tered John­son & John­son.

                                  1 Reply Last reply
                                  0
                                  • E Offline
                                    E Offline
                                    E_L
                                    wrote on sidst redigeret af
                                    #157

                                    As part of No­var­tis' in­vest­ment, which in­cludes sev­en new fa­cil­i­ties, the com­pa­ny said it will be able to make all of its "key" med­i­cines "end-to-end" in the US. It was­n't im­me­di­ate­ly clear how the com­pa­ny was defin­ing "key" drugs, and if that meant some med­i­cines it sells in the US will still be man­u­fac­tured else­where.

                                    1 Reply Last reply
                                    0
                                    • L Offline
                                      L Offline
                                      lahn1
                                      wrote on sidst redigeret af
                                      #158

                                      Hvem skal man investere i for at få nytte af alle de fabrik opførelser ? Hvem laver produktionslinjerne ?

                                      1 Reply Last reply
                                      0
                                      • G Offline
                                        G Offline
                                        GUHO
                                        wrote on sidst redigeret af
                                        #159

                                        I første omgang tænker jeg arkitekter, rådgivere og entreprenører indenfor byg og anlæg. Det marked burde have svære tider på grund af rentehoppet, men har enorm efterspørgsel på grund af Novos fabriksudvidelser

                                        1 Reply Last reply
                                        0
                                        • E Offline
                                          E Offline
                                          E_L
                                          wrote on sidst redigeret af
                                          #160

                                          Acasunlimab, an Fc-inert PD-L1×4-1BB bispecific antibody, combined with PD-1 blockade potentiates antitumor immunity via complementary immune modulatory effects https://jitc.bmj.com/content/13/4/e011377

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper